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Background: Group 1 grass pollen allergens are a major cause of allergic disease. Specific immunotherapy
involving controlled administration of allergens can be used as a disease-modifying treatment for such disease.
Recombinant allergen variants with reduced IgE binding capacity may be used as component in such vaccines, as
they may induce fewer treatment side effects than materials currently in use. A mutated variant of the immunodominant
C-terminal domain of the group 1 grass pollen allergen Phl p 1 was recently established through an approach that used a
set of human monoclonal IgE as a guide to identify mutations that disturbed IgE-allergen interactions. Further analysis of
this domain is required to establish its potential for use in treatment.
Methods: GST-tagged wild-type and mutated C-terminal domains of Phl p 1 were produced in Escherichia coli
TUNER(DE3). The products were purified by affinity chromatography on immobilized glutathione. GST was removed by
enzymatic cleavage and tag-free products were purified by size exclusion chromatography. Products were assessed by
SDS-PAGE, circular dichroism spectroscopy, differential scanning fluorimetry and dynamic light scattering. Rats were
immunized with GST-tagged and tag-free mutated C-terminal domain of Phl p 1. Antigen-binding properties of
induced antibodies were assessed by immunochemical analysis.
Results: The mutated domain has a structure very similar to that of the wild-type domain as determined by circular
dichroism, but a reduced thermal stability. Immunization of rats demonstrates that this IgE-hyporeactive domain,
despite its three sequence modifications (K8A, N11A, D55A), is able to induce antibodies that substantially block the
binding of allergic subjects’ IgE to the wild-type allergen.
Conclusions: It is concluded that this IgE-hyporeactive molecule can be produced in folded form and that it is able to
induce an antibody response that efficiently competes with IgE recognition of Phl p 1. These findings suggest that it, or a
further evolved variant thereof, is a candidate for use as a component in specific immunotherapy against grass pollen allergy.
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Allergic disease substantially reduces the quality of life
of affected subjects and incurs large costs to society as a
whole. This disease of the immune system, is initiated by
activation of effector cells carrying antibodies of the IgE
isotype by their antigen, so-called allergens [1]. Aller-
gens, often otherwise harmless compounds, thus repre-
sent one of the key components of the disease and
measures that alter their ability to activate effector cells
may affect allergic disease conditions.
Procedures to treat allergic disease mostly target the
symptoms of disease and these procedures are not curative.* Correspondence: mats.ohlin@immun.lth.se
1Dept. of Immunotechnology, Lund University, Medicon Village building 406,
S-223 81, Lund, Sweden
Full list of author information is available at the end of the article
© 2015 Levin et al. This is an Open Access art
(http://creativecommons.org/licenses/by/4.0),
provided the original work is properly credited
creativecommons.org/publicdomain/zero/1.0/The only treatment option with potential to cure allergic
disease is vaccination, so-called specific immunotherapy
(SIT) [2], that directly interferes with the immune reactions
that cause disease. Such treatment may for instance induce
allergen-specific antibodies of the IgG isotype that compete
with allergy-inducing IgE for binding to allergens, thereby
preventing the activation of effector cells. Such vaccination
is, however, often accompanied by extensive side effects, in
particular allergic reactions to the vaccine preparation that
contains unmodified allergen(s). To enhance the tolerability
profile of such vaccines attempts have been made to dimin-
ish the allergenicity of vaccine components while maintain-
ing their ability to induce protective immunity. Such
allergen variants, molecules that may be found in nature or
may be created in vitro for instance through mutagenesis,
shuffling of the order of different parts of allergens, or byicle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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ability to induce allergic symptoms, are termed hypoaller-
gens [3]. Such hypoallergens are now used for development
of new vaccines to be used in SIT.
Grass pollen is a major cause of seasonal allergy in many
parts of the world [4]. Consequently vaccines targeting such
allergies have been established and are commercially avail-
able. These vaccines are based on natural pollen extracts,
for instance from timothy (Phleum pratense), and they carry
a risk of inducing allergy-type side effects. Pollens contain
numerous allergens but the group 1 and group 5 pollen al-
lergens are among those most commonly contributing to
IgE binding [5,6]. More defined recombinant allergen vac-
cines, specifically incorporating some of the major allergens,
including group 1 pollen allergens, of grass pollen have been
created to investigate their potential as defined vaccines [7].
Group 1 pollen allergens are made up of two domains.
Its C-terminal domain appears to be immunodominant in
terms of induction of allergen-specific IgE in humans [8].
We recently developed an IgE-hyporeactive variant of this
particular domain of the timothy group 1 allergen, Phl
p 1, through the introduction of three mutations (N8A,
K11A, D55A), mutations that were selected based on their
ability to reduce IgE binding [9]. This knowledge-based
approach depended on the utilization of allergen-specific
monoclonal antibody specificities developed from the IgE
repertoire of allergic subjects [8-11]. To allow further as-
sessment of the IgE-hyporeactive domain developed this
way, we now define a strategy to produce large quantities
of the protein in Escherichia coli. We also define its abilityFigure 1 SDS-PAGE analysis of the product obtained during the different s
(A) and wild-type allergen (B) C-terminal domain of Phl p 1.0102. The follo
flow through (FT) and wash (W) fractions, eluted fractions (pool), the pool
protein (final). Dilutions of the samples prior to electrophoresis are indicate
domain, depicted to the right, migrates as a single band, although at a slig
(11 kDa). The purified GST-coupled protein (37 kDa) as well as GST (26 kDato form a folded protein structure and its stability upon ther-
mal stress. Finally we determine its ability to induce anti-
bodies that also target the unmodified protein sequence, a
feature important if it, or a variant of it, is to be useful in SIT.
Results
Recombinant production of allergen
Laboratory small-scale production of GST-allergen domain
fusion protein yielded low quantities of recombinant pro-
tein [9]. To facilitate further studies of the protein and in
particular to allow for production of sufficient amounts of a
GST-tag-free product, the production methodology was op-
timized [9], as detailed in the Methods section. To have ac-
cess to larger quantities of pure protein for structural
studies and studies of immunogenicity, we used a purifica-
tion scheme based on GST binding to immobilized gluta-
thione, cleavage of the product with PreScission protease,
and removal of uncleaved enzyme and GST by use of size
exclusion chromatography. This approach provided >90%
pure product of the mutated version of the C-terminal do-
main of Phl p 1 (Figure 1). As expected, the purified protein
migrated as a single product during SDS–PAGE with an
apparent molecular weight of 14 kDa protein, slightly above
the expected size. The yield of purified protein was approxi-
mately 1 mg per litre of cultured bacteria.
To assess whether or not the developed processes relied
on any specific features inherent only to the mutated version
of the C-terminal domain of Phl p 1 we also produced and
purified the module with the wild-type sequence using the
same approach. These efforts yielded a product (Figure 1)GST 
Phl p 1  
C-term 
GST - Phl p 1  
C-term 
teps during the purification of the IgE hyporeactive (K8A, N11A, D55A)
wing fractions were analysed: Lysate (L), soluble fraction (S), column
after digestion with PreScission protease (+3C), and the final, purified
d above the lanes. The purified non-GST fused IgE hyporeactive
htly higher apparent molecular weight (14 kDa) than expected
) are clearly visible with expected molecular weights.
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production of the IgE-hyporeactive domain.Recombinant protein is monodispersed and well-folded
The state of aggregation of the purified allergen and
hypoallergen was investigated with gel filtration. Both
the wild-type and the mutant protein eluted with vol-
umes corresponding to a molecular mass of approxi-
mately 20 kDa, suggesting that these proteins exist as
dimers in solution (data not shown). DLS (data notFigure 2 Analysis of folding by CD spectroscopy. A. CD spectra of instrum
260 nm. The spectra of the C-terminal domain of Phl p 1.0102 is shown in
red. Inset zooms in on the spectra between 200–240 nm. B. CD differenceshown) indicated that both protein preparations were
monodisperse and contained low amounts of aggregates.
CD spectroscopy was used to estimate secondary
structure content of the proteins at +4°C. Based on the
similarity of the CD spectra (Figure 2) it is concluded
that the content of structure of the two proteins is simi-
lar at low temperatures. In summary, there is no indica-
tion, within the accuracy and methodological limits of
CD spectroscopy, that the K8A, N11A, D55A substitu-
tions cause significant structural modifications of the
protein.ent ellipticity output. Spectra were buffer subtracted and nulled at
blue and its IgE-hyporeactive (K8A, N11A, D55A) variant is shown in
spectrum of the two proteins.
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using Thermofluor technology. The calculated melting
temperatures were 48.5 +/− 2.5°C for the allergen fragment
and 38.8 +/− 2.5°C for the hypoallergen fragment (Figure 3).
Thus the mutant protein unfolded at a temperature almost
10°C lower than the wild-type protein.
Recombinant protein induce allergen-specific antibodies
in rats
SIT has been shown to induce antibodies of the IgG isotype
with the ability to interfere with the binding of patient IgE
to the allergen and it is likely beneficial to retain such an
ability also in a modified hypoallergenic protein. We there-
fore assessed the ability of the produced IgE-hyporeactive
domain to induce antibodies of the IgG isotype with specifi-
city for the wild-type Phl p 1 allergen by immunization of
rats and, if so, if these antibodies carried the desired ability
to block the binding of serum IgE from allergic patients to
Phl p 1. Indeed, the IgE-hyporeactive domain turned out to
be immunogenic in rats and sera from rats immunized with
both the GST-tag carrying recombinant protein as well as
the PreScission protease-treated and purified protein con-
tained high levels of IgG with an ability to bind both the
IgE-hyporeactive domain and the wild-type Phl p 1 at com-
parable levels (Figure 4A, B). Notably, rats immunized with
the IgE-hyporeactive protein also developed significant
levels of anti-GST IgG, indicating presence of residual GST
even in the PreScission protease treated and purified pro-
tein preparation, although at levels too low to be detected
using standard SDS-PAGE analysis (Figure 4C). The unex-
pected GST-reactivity in this group of rats could potentially
also be explained by cross-reactivity of IgG-responses de-
veloped against Phl p 1. To further investigate this matter
inhibition assays were performed, in which the ability of
both Phl p 1 and GST to block binding of rat IgG to
immobilized Phl p 1 was assessed (Additional file 1:Figure 3 Thermal denaturation assay using Thermofluor technology
with SYPRO© dye. Unfolding fluorescent curves for the C-terminal
domain of Phl p 1.0102 (red, purple) and its IgE-hyporeactive sequence
variant (K8A, N11A, D55A) (blue, green). A shift of 9.7°C was observed
between the IgE-hyporeactive variant and the wild-type protein.Figure S1). While Phl p 1 efficiently blocked the
antigen-specific interaction between polyclonal rat IgG
and the immobilized allergen, GST failed to do so even
at high concentrations (10 μg/ml). These results cannot
fully exclude the possibility that at small proportion of
the Phl p 1-reactive rat IgG is cross-reactive to GST, or
that these antibodies bind to GST with an affinity too
low to allow GST in solution to block antibody binding
to Phl p 1. However, it should be considered more likely
that the detected GST-reactivity is due to traces of GST
left in the PreScission protease treated preparation,
traces that are able to induce humoral immunity to GST
following immunization. Sera from control rats immu-
nized with PBS showed no relevant reactivity with Phl p
1 (Figure 4D). Importantly, these findings demonstrate
that the mutations introduced into the IgE-hyporeactive
domain do not alter the protein in a way that prevent it
from inducing antibody responses specific also for the
wild-type Phl p 1 protein.
We then assessed the ability of the rat antibodies induced
against the IgE-hyporeactive C-terminal domain of Phl p 1
to inhibit the binding of serum IgE from allergic patients to
wild-type intact Phl p 1 in a competitive ELISA assay. The
induced antibodies of all four immunized rats did indeed
interfere (20-88% inhibition; average: 66%) with patient
IgE reactivity to immobilized intact Phl p 1 (Table 1 and
Additional file 1: Figure S2). In contrast, antibodies from a
control rat immunized with PBS had no effect on patient
IgE binding to the allergen (Additional file 1: Figure S2).
Thus, despite the fact that the recombinant module used for
immunization only represented a part (approximately 42%
of the molecular mass) of the entire intact allergen, the anti-
bodies it induced were able to a block a substantial part of
most patients’ IgE to the intact allergen. This demonstrates
the ability of the mutated IgE-hyporeactive domain to pro-
voke antibody responses that target major IgE-reactive areas
on the intact, wild-type Phl p 1 allergen, a property that is
likely to be highly beneficial in SIT of allergic disease. As the
IgE of a few patients (Table 1) was not efficiently blocked
from binding Phl p 1, it is possible that the immune re-
sponse of some subjects is not so focused on the otherwise
immunodominant [8] C-terminal domain of Phl p 1. Further
studies will be required to address this matter in larger pa-
tient cohorts.
Discussion
IgE-hyporactive proteins with potential to induce anti-
bodies that prevent IgE binding to wild-type allergen are
candidates for development of improved vaccines for use
in SIT against allergy. We recently defined a mutated vari-
ant of the immunodominant domain of Phl p 1, a major
grass pollen allergen, with substantially reduced ability to
bind Phl p 1-specific IgE [9]. To allow further studies of
this module and to facilitate a decision-making process
Figure 4 Immunoreactivity of antibodies in rat serum after immunization with the K8A, N11A, D55A mutant of the C-terminal domain of Phl p 1.0102
without the GST fusion tag (A-C) or PBS (D). Four rats were used for each immunization. Reactivity was tested against the non-GST fused K8A, N11A, D55A
mutant (A and D), wild-type intact Phl p 1.0102 (B) and GST (C). Serum antibodies obtained from rats immunized with the IgE-hyporeactive mutant
C-terminal domain of Phl p 1.0102 coupled to GST showed similar reactivity to the non-GST fused K8A, N11A, D55A mutant and the intact wild-type Phl
p 1.0102, while the reactivity to GST was considerably higher (data not shown).
Table 1 Inhibition of binding of patients’ serum IgE (diluted
1:25) to intact Phl p 1 by polyclonal rat antibodies (diluted
1:1000) induced by immunization with the IgE-hyporeactive
domain without the GST fusion tag
Inhibition of serum IgE binding* (%)
Patient Rat 1 Rat 2 Rat 3 Rat 4 Mean ± SD (%)
1 83 85 84 78 83 ± 3
2 25 42 37 20 31 ± 10
3 83 74 79 71 77 ± 5
4 49 51 50 39 47 ± 6
5 67 65 51 52 59 ± 8
6 84 81 81 80 81 ± 2
7 88 85 85 87 86 ± 2
8 60 55 73 73 65 ± 9
*As compared to reactivity in the presence of sera from control rat immunized
with PBS.
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for further molecular adaptation, we used a production
methodology [9] that allowed us to obtain mg quan-
tities of protein for further analysis. By use of the E. coli
TUNER(DE3) strain, that allows more controlled and
even uptake of the inducer (IPTG) of protein produc-
tion, reduction of the production temperature, and ex-
tension of the production time we were able to obtain
multi-mg quantities of the fusion protein product for
further detailed studies of its properties. Elimination
of the N-terminal GST fusion tag was achieved using
PreScission protease treatment and subsequent chro-
matorgraphy, as determined by gel electrophoresis. Al-
though trace amounts of GST appear to remain in the
purified, PreScission protease treated, tag-free protein
preparation, the procedure was shown to provide a
well-folded domain for use in applications that require
several mg of product.
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formational epitopes that depend on an intact protein
structure [12]. Indeed, the two determined crystal struc-
tures of human IgE fragments in complex with their re-
spective allergens illustrate this aspect of IgE-allergen
interactions [13,14]. Consequently, strategies to develop
hypoallergenic molecules in some respects often rely on
destruction of protein fold [15,16]. This particular IgE-
hyporeactive module [9], however, retain its folded char-
acter, which is undistinguishable from that of the wild-
type domain as determined by CD. The approach [9]
whereby it was created may in part be responsible for
this feature. This process relied on identification of mul-
tiple surface-exposed residues that are directly respon-
sible for monoclonal human IgE binding that also
translate into reduced binding to polyclonal IgE [9]. Im-
portantly, amino acid side chains that are involved in es-
tablishing the core of the protein fold are largely not
affected by the mutations. We consequently believe that
such a minimal, knowledge-based, approach is more
likely than a more extensive mutagenesis approach to
minimally affect protein structure and it will leave much
of the surface that is not critical for IgE binding un-
touched. The process thus has the potential to induce a
wide range of antibodies that also target the natural al-
lergen, the purpose of an SIT strategy.
Although the hypoallergen was folded at +4°C it was
more sensitive to thermal denaturation and melted in vitro
at a temperature close to normal body temperature. The
precise molecular effect responsible for this destabilization
towards heating is not known. One of the modifications of
the IgE-hyporeactive variants (N11A), however, affects a
residue whose side chain has the potential to establish two
polar interactions, more specifically with protein backbone
amino groups of residues N13 and Y14 (Additional file 1:
Figure S3). It is conceivable that this mutation at least in
part contributes to the thermal destabilization of the IgE-
hyporeactive properties of the mutant protein but further
investigations are required to assess the precise role of the
these modifications in molecular destabilization. Neverthe-
less, despite the fact that mutant module is more sensitive
towards thermal denaturation, it has been possible to estab-
lish a production and purification procedure that produces
a well-folded protein.
Conclusions
In conclusion, we herein demonstrate features of a folded,
immunogenic, recombinant IgE-hyporeactive domain of the
major grass pollen allergen Phl p 1, a domain that has been
developed through a knowledge-based approach [9]. It is
suggested that this domain, variants of it, or ultimately other
IgE-hyporeactive domains established by this methodology,
after extensive assessment of safety and efficacy, has the po-
tential to find application in safer allergy vaccination.Methods
Production and purification of recombinant protein
Codon-optimised genes (Additional file 1: Figure S4) en-
coding the C-terminal domain of Phl p 1.0102 or a mu-
tant (K8A, N11A, D55A; residues are numbered starting
with the KVTF sequence in the beginning of the C-
terminal domain) thereof with reduced IgE-binding cap-
acity have been described in the past [9]. These genes
were cloned into the pGEX-6P1-vector (GE Healthcare,
Uppsala, Sweden) and originally used for production of
recombinant protein in E. coli T7 express (New England
Biolabs, Ipswich, MA). Improved yield [9] was obtained
using strain E. coli TUNER (DE3) (F−ompT hsdSB
(rB
− mB
−) gal dcm lacY1(DE3)) (Novagen). This strain is
derived from E. coli BL21 and lacks the lacY gene encod-
ing the Lac permease. In contrast to the previously used
strain [9] the T7 RNA polymerase is driven from the
lacUV5 promoter and present in a lambda prophage.
Briefly, E. coli TUNER(DE3) was transformed with either
plasmids encoding the C-terminal domain of Phl p
1.0102 or the mutant thereof. The cells were grown in of
LB broth (Difco) supplemented with 100 μg/ml ampicillin
in 5 L Erlenmeyer flasks with indentations (1 L/flask) at
18°C, 200 rpm. At OD600 ~ 0.5, IPTG was added to a final
concentration of 1 mM. 18 hours after induction, cells
were harvested in a JLA 8.1000 rotor, 8000×g, 4°C,
15 min, and the pellets were stored at −80°C or used dir-
ectly for preparation of soluble extract. The use of a low
production temperature (18°C) and an extended produc-
tion phase (18 h) were important parameters to reach a
high product yield. The pellets from 1 L culture were re-
suspended in 20 ml PBS, pH 7.3, supplemented with one
tablet Complete Protease Inhibitor, EDTA-free (Roche).
The cell suspension was passed twice through a French
Pressure cell at 18 000 psi. The lysate was centrifuged in a
Beckman Ti 50.2 rotor, 45 000 rpm, 60 min, 4°C, and the
supernatant (soluble fraction) was collected and passed
through a 0.45 μm filter.
The soluble fraction was used for affinity chromatog-
raphy. A 5 ml GSTrap FF column (GE Healthcare) was
connected to an ÄKTA Avant system (GE Healthcare). The
column was run at room temperature, while fractions were
collected at 4°C. The column was washed with PBS, pH 7.3
until a stable signal at 280 nm was obtained. Bound protein
was eluted with 10 column volumes 50 mM Tris–HCl,
150 mM NaCl, 40 mM reduced glutathione (pH 8.0). Peak
fractions were analyzed with SDS-PAGE, and fractions con-
taining allergen were pooled. The pooled fractions were
concentrated and the buffer was exchanged to 50 mM Tris,
150 mM NaCl, 1 mM EDTA (pH 8.0) using Vivaspin
Turbo 15 ultrafiltration spin columns (molecular weight
cutoff: 10,000 Da). The glutathione S-transferase (GST)-tag
was removed with PreScission protease (13 u/mg protein)
(GE Healthcare). DTT was added to the reaction mixture
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was left at 4°C for one day. To separate allergen from Pre-
Scission protease and GST and other contaminating pro-
teins, size exclusion chromatography was performed using
a HiLoad 26/600 Superdex 200 pg gel filtration column
(GE Healthcare). The column was run at 4°C, with a flow
rate of 2.6 ml/min 50 mM Tris, 150 mM NaCl, pH 8.0, and
4 ml fractions were collected. Peak fractions were analyzed
with SDS-PAGE, and fractions containing allergen were
pooled. The pooled fractions were concentrated and the
buffer was exchanged to PBS using Vivaspin Turbo 15
ultrafiltration spin columns (molecular weight cutoff:
3,000 Da). The concentrated protein solution was passed
through a 0.22 μm sterile filter and was stored at +4°C.
GST, not coupled to allergen, was produced in E. coli T7
express (New England Biolabs) using the pGEX-6P-1 vector
(GE Healthcare) without any gene insert, and purified using
GSTrap FF columns (GE Healthcare), as previously de-
scribed [9].
Immunization of rats with IgE-hyporeactive protein
Rats were immunized four times with either (1) recombin-
ant C-terminal domain carrying the K8A, N11A, D55A
modifications fused to GST, or (2) a GST-free variant
thereof purified following PreScission protease treatment
(approximately 200 (primary immunization) or 100 (booster
immunization) μg protein was used/injection), or (3) PBS, in
combination with Freund’s adjuvant (complete adjuvant was
used for primary immunization while incomplete adjuvant
was used for booster immunization) (Agrisera, Vännäs,
Sweden). The procedure was approved by the Ethical Com-
mittee on Animal Experiments in Umeå, Sweden.
Determination of specific IgG levels in rat serum, specific
IgE levels in patient serum and ability to inhibit patient
IgE binding to Phl p 1
To determine the levels of specific IgG in serum from im-
munized rats or specific IgE levels in serum from allergic
donors, recombinant Phl p 1.0102 (Biomay, Vienna,
Austria), the IgE-hyporeactive mutant C-terminal domain
thereof or GST were coated into microtiter plates (Corning,
Corning, NY) at a concentration of 1 μg/ml or 0.2 μg/ml in
PBS. After washing with 0.9% (w/v) NaCl and 0.05% (v/v)
Tween 20, rat or patient sera, diluted to suitable concentra-
tions in blocking buffer (1% (w/v) non-fat dry milk and
0.05% (v/v) Tween 20 in PBS), was added and incubated for
1 h at 37°C. After an additional wash step bound rat IgG
was detected using a horse-radish peroxidase-labelled goat
anti-rat IgG antiserum (Bethyl Laboratories, Montgomery,
TX) using 1-Step Ultra TM-ELISA substrate (Thermo
Scientific, Rockford, IL) as chromogen. Absorbance was
measured at 450 nm. Bound patient IgE was detected using
a horse-radish peroxidase-labelled anti-IgE antiserum (KPL,
Guilford, UK) and chemiluminescent substrate (SuperSignalELISA Femto Maximum Sensitivity Substrate, Thermo
Scientific).
The ability of serum from immunized rats to inhibit
patient IgE reactivity to Phl p 1 was assessed using a
competitive ELISA assay. Sera had been obtained fol-
lowing informed consent from allergic subjects, as ap-
proved by the Regional Ethical Committee at Lund
University. Microtiter plates were coated with Phl p
1.0102 at a concentration of 0.2 μg/ml in PBS and
washed as described above. Next, serum from rats im-
munized with either the IgE-hyporeactive domain, not
coupled to GST, or PBS, diluted 1:1000 in blocking buf-
fer or PBS as reference, was added and incubated for 1 h
at 37°C. Without washing, serum from allergic patients
were added to the wells pre-incubated with rat serum or
PBS at a final 1:25 dilution and incubated for 1 h at
37°C. After washing, bound IgE was detected using a
horse-radish peroxidase-labelled anti-IgE antiserum and
chemiluminescent substrate. The degree of inhibition was
assigned by relating the signal obtained from the wells
pre-incubated with rat serum to the well pre-incubated
with PBS.Circular dichroism spectroscopy
Circular dichroism (CD) spectroscopy measurements
were performed on a Jasco J-810 spectropolarimeter
equipped with a Jasco CDF-426S Peltier set to 4°C. The
protein concentration used was 0.6 mg/ml and averages
of five scans were baseline-subtracted (buffer: 100 mM
ammonium phosphate, 10 mM potassium phosphate,
pH 7.3).Thermal stability assay
To evaluate the effects of amino acid substitutions on
the overall thermal stability for wild type and mutant
allergen, differential scanning fluorimetry (DSF) assays
were performed using a Mx3005P qPCR system (Strata-
gene). The protein concentration was 120 μM in
100 mM sodium sulphate, 20 mM potassium phosphate,
pH7.3, containing 5 × SYPRO orange dye (1:1000 dilu-
tion) (Invitrogen). The fluorescence was measured as a
function of increasing temperature at the rate of 1°C/
min (excitation wavelength: 498 nm; emission wave-
length: 610 nm).Dynamic Light Scattering (DLS) measurements
DLS measurements were performed at 10°C using a
Malvern Zetasizer DLS instrument. Data analysis was
done using the Zetasizer software supplied with the in-
strument. Protein (0.6 mg/ml) in buffer 100 mM ammo-
nium phosphate, 10 mM potassium phosphate, pH 7.3
was used for the analysis.
Levin et al. BMC Biotechnology  (2015) 15:52 Page 8 of 8Additional file
Additional file 1: Supplementary Information.
Abbreviations
CD: Circular dichroism; DLS: Dynamic light scattering; DSF: Differential
scanning fluorimetry; GST: Glutathione S-transferase; SIT: Specific
immunotherapy.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
ML participated in the study design, performed evaluation of the sera from rats
immunized with the IgE-hyporeactive module, analysed data and participated
in the manuscript preparation. HO performed biophysical characterization,
analysed data and participated in the manuscript preparation. CVW was
responsible for and planned cloning, large scale production and purification of
the IgE-hyporeactive module, and participated in the manuscript preparation.
MO was responsible for the study design, manuscript preparation and editing
as well as participated in data analysis. All authors read and approved the final
version of the manuscript.
Acknowledgements
We acknowledge the financial support of this study by Stiftelsen Olle Engkvist
Byggmästare, and the Swedish Research Council (grant number 521-2011-3282).
Part of the work was facilitated by the Lund Protein Production Platform and the
Crystallization facility at the MAX IV laboratory, Lund University, Sweden. The
funding sources had no influence on the design of the study, on the analysis or
the interpretation of the data, in the writing of the manuscript, or in the decision
to submit the manuscript for publication.
Author details
1Dept. of Immunotechnology, Lund University, Medicon Village building 406,
S-223 81, Lund, Sweden. 2Crystallization facility at the MAX IV laboratory and
Lund University, Lund, Sweden. 3Lund Protein Production Platform (LP3),
Lund University, Lund, Sweden.
Received: 2 September 2014 Accepted: 22 April 2015
References
1. Gould HJ, Sutton BJ. IgE in allergy and asthma today. Nat Rev Immunol.
2008;8:205–17.
2. Linhart B, Valenta R. Vaccines for allergy. Curr Opin Immunol. 2012;24:354–60.
3. Valenta R, Linhart B, Swoboda I, Niederberger V. Recombinant allergens for
allergen-specific immunotherapy: 10 years anniversary of immunotherapy
with recombinant allergens. Allergy. 2011;66:775–83.
4. Bauchau V, Durham SR. Prevalence and rate of diagnosis of allergic rhinitis
in Europe. Eur Respir J. 2004;24:758–64.
5. Laffer S, Vrtala S, Duchêne M, van Ree R, Kraft D, Scheiner O, et al. IgE-
binding capacity of recombinant timothy grass (Phleum pratense) pollen
allergens. J Allergy Clin Immunol. 1994;94:88–94.
6. Niederberger V, Laffer S, Fröschl R, Kraft D, Rumpold H, Kapiotis S, et al. IgE
antibodies to recombinant pollen allergens (Phl p 1, Phl p 2, Phl p 5, and
Bet v 2) account for a high percentage of grass pollen-specific IgE. J Allergy
Clin Immunol. 1998;101:258–64.
7. Jutel M, Jaeger L, Suck R, Meyer H, Fiebig H, Cromwell O. Allergen-specific
immunotherapy with recombinant grass pollen allergens. J Allergy Clin
Immunol. 2005;116:608–13.
8. Flicker S, Steinberger P, Ball T, Krauth MT, Verdino P, Valent P, et al. Spatial
clustering of the IgE epitopes on the major timothy grass pollen allergen
Phl p 1: importance for allergenic activity. J Allergy Clin Immunol.
2006;117:1336–43.
9. Levin M, Rydnert F, Källström E, Tan LW, Wormald PJ, Lindstedt M, et al. Phl
p 1-specific human monoclonal IgE and design of a hypoallergenic group 1
grass pollen allergen fragment. J Immunol. 2013;191:551–60.
10. Gadermaier E, Levin M, Flicker S, Ohlin M. The human IgE repertoire. Int
Arch Allergy Immunol. 2014;163:77–91.11. Persson H, Karbalaei Sadegh M, Greiff L, Ohlin M. Delineating the specificity of
an IgE-encoding transcriptome. J Allergy Clin Immunol. 2007;120:1186–92.
12. Aalberse RC, Crameri R. IgE-binding epitopes: a reappraisal. Allergy.
2011;66:1261–74.
13. Niemi M, Jylhä S, Laukkanen ML, Söderlund H, Mäkinen-Kiljunen S, Kallio JM,
et al. Molecular interactions between a recombinant IgE antibody and the
beta-lactoglobulin allergen. Structure. 2007;15:1413–21.
14. Padavattan S, Flicker S, Schirmer T, Madritsch C, Randow S, Reese G, et al. High-
affinity IgE recognition of a conformational epitope of the major respiratory
allergen Phl p 2 as revealed by X-ray crystallography. J Immunol. 2009;182:2141–51.
15. Linhart B, Valenta R. Mechanisms underlying allergy vaccination with
recombinant hypoallergenic allergen derivatives. Vaccine. 2012;30:4328–35.
16. Vrtala S, Focke-Tejkl M, Swoboda I, Kraft D, Valenta R. Strategies for converting
allergens into hypoallergenic vaccine candidates. Methods. 2004;32:313–20.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
